Status:
UNKNOWN
Comparison of Combined Intravitreal Bevacizumab and Oral Acetazolamide Versus Intravitreal Bevacizumab Alone for the Treatment of Macular Edema Secondary to Retinal Vein Occlusions
Lead Sponsor:
Shahid Beheshti University of Medical Sciences
Conditions:
Macular Edema
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
In this study, which will be performed as a randomized clinical trial, all patients with macular edema with central involvement (central macular thickness greater than 300 μm) and corrected vision les...
Eligibility Criteria
Inclusion
- 20 / 400≤ Best Corrected Visual Acuity ≤20 / 40
- Central macular thickness \<300 μm
- The onset of the disease is less than three years
- No other eye diseases that affect the evaluation and process of this study.
Exclusion
- It is not possible to provide informed consent.
- Patients who are prohibited from taking oral acetazolamide (renal failure, hepatic failure, history of allergies)
- Other eye diseases that affect the evaluation and process of this study. Including diabetes retinopathy
- History of retinal laser photocoagulation
Key Trial Info
Start Date :
March 12 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
57 Patients enrolled
Trial Details
Trial ID
NCT05290948
Start Date
March 12 2022
End Date
December 1 2022
Last Update
March 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ophthalmic Research center
Tehran, Iran, 1659756151